Objective: There is ongoing debate about the efficacy of polyvalent immunoglobulins as adjunctive therapy for sepsis or septic shock. Two meta-analyses by the Cochrane collaboration calculated a significant reduction in mortality. However, data of the largest study were missing in one, and a subset of four highquality studies failed to show an effect in the other. To broaden the database, we performed a meta-analysis of all randomized controlled studies published so far.
P olyvalent immunoglobulin preparations are widely used as adjunctive therapy for sepsis or septic shock, but their efficacy is still a matter of debate (1) . In experimental studies, it was shown that polyvalent immunoglobulins can improve opsonization (2) , prevent nonspecific complement activation (3), protect against the antibioticinduced liberation of endotoxin (4) , and neutralize endotoxin (5) as well as a wide variety of superantigens (6) .
However, therapeutic trials were mostly performed on a small number of patients and most of them did not have the power to detect significant differences. A meta-analysis published by the Cochrane Library (7) calculated a significant effect on the overall mortality (relative risk of death [RR] ϭ 0.64; 95% confidence interval [CI] 0.5-0.81) and an even more pronounced effect for immunoglobulin A (IgA)-and immunoglobulin M (IgM)-enriched immunoglobulins (RR ϭ 0.48, 95% CI 0.30 -0.76). However, this meta-analysis has been questioned because the result of the largest trial so far, the Score-Based Immunoglobulin G Treatment in Sepsis (SBITS) trial (8) , was not included.
This trial (8) was included in another systematic review from the Nordic Cochrane Center (9) . For a total of 21 studies, this meta-analysis also calculated a significant effect on mortality (RR ϭ 0.77, 95% CI 0.68 -0.88). However, because a subgroup of four high-quality trials failed to demonstrate a reduction in mortality, the authors concluded that polyclonal immunoglobulin should not be used for the treatment of sepsis except in randomized clinical trials (9) .
To date, five newer studies (10 -14) have been published and some additional trials identified, so we decided to conduct a new systematic review. In contrast to our predecessors, we summarized data on adults and neonates separately since the immunologic state and the rationale for the adjunctive administration of immunoglobulins differ considerably between the two groups (15) .
METHODS
Study Identification. We searched for all trials investigating the therapeutic effect of polyclonal immunoglobulins on mortality in adults, children, or neonates in suspected or proven sepsis or septic shock with no restrictions for language or year of publication. Studies focusing solely on prevention of sepsis were excluded. An electronic database search was performed for MEDLINE, EMBASE, and the Cochrane Library for the following sequence of keywords (immunoglobulins or immunoglobulins, intravenous or immunoglobulin G or immunoglobulin M) and (sepsis or severe sepsis or septic shock or septicaemia or septicemia or sepsis syndrome or bacterial infections or bacterial infection) and (human or humans) and (randomized controlled trial or comparative trial or clinical trial or case control study or clinical outcome). The query was last updated on August 14, 2006 . Additionally, all references of the identified studies as well as those of review papers and personal files were checked for further studies. Manufacturing companies were asked for unpublished results, and authors were contacted for further information about the methodological quality of the trials.
Study Selection Criteria. To be eligible, trials had to fulfill the following criteria: 1) Patients had to be characterized as being septic or having septic shock according to clinical variables that were equivalent to the 1992 Society of Critical Care Medicine/American College of Chest Physicians Consensus Conference; 2) trials had to be randomized; and 3) 7S and not 5S immunoglobulins had to be used. (5S immunoglobulins are incomplete molecules without the fc-part. They have reduced biological function and were later replaced by 7S preparations.)
The primary and only outcome parameter was the impact of immunoglobulins on the reported mortality. If reported, the 28-day mortality was used for the calculations; otherwise, the intensive care unit (ICU) or hospital mortality was used. One study (16) reported the 7-day and 56-day mortality rates. In this case, the latter was used. For all trials, the calculation of the effect of immunoglobulin on mortality was based on overall mortality. Furthermore, intention-to-treat results were used if available. Otherwise, results were recalculated to an intention-to-treat base if possible.
Data Extraction and Assessment of Methodological Quality of Primary Studies. Data were extracted by each of the four authors independently and then compared. Disagreements were solely the result of errors, and agreement could be reached in each case.
The methodological quality of the studies was assessed by nine parameters that influence the ability of the study to generate a true estimate of treatment effect (17) ( Table 1) . The methodological quality of each study was scored (range 0 -14) independently by each author. Disagreement was resolved by consensus. A score of Ն12 was set as a criterion for higher methodological quality.
A Priori Hypotheses Regarding Sources of Heterogeneity. A priori, we decided to summarize data for two subgroups: IgG immunoglobulins enriched with IgA and IgM vs. those that contain solely IgG.
Data Synthesis. Relative risks were computed and combined in a meta-analysis by the Mantel-Haenszel method with use of RevMan software, version 4.2.3 (Cochrane; available from http://www.cochrane.org). A fixed-effect model was used which assumes that the true effect of the intervention is the same in all of the included trials, differences between study results being ascribed to sampling error. Variations in study results were referred to as heterogeneity. Large studies with high event rates received the highest weight in the metaanalysis. The a priori primary hypothesis for exploring sources of heterogeneity was the influence of the type of immunoglobulin.
Tests for heterogeneity were performed with use of the method of DerSimonian and Laird (18) . A test for interaction was also performed (19) .
The difference between two estimated risks was checked for significance according to the method described by Altman and Bland (20) .
RESULTS
We identified 959 citations from MED-LINE and 928 from EMBASE. From these citations as well as from the Cochrane Library and personal files, an initial eligibility screening was conducted. This search resulted in 52 articles or abstracts describing the therapeutic use of polyvalent immunoglobulins in sepsis or septic shock that were selected for further evaluation. After a detailed analysis, 25 of them were excluded for the following reasons: historical control or retrospective data only (21) (22) (23) , no randomization (24 -28), sepsis criteria not fulfilled (29, 30) , an interim analysis of a trial (31, 32) , hyperimmunoglobulin (33, 34) , duplicate publications (32, (35) (36) (37) , and mortality not a primary outcome parameter (38 -41) . The trial reported by Jesdinsky et al. (42) was excluded because it involved pa-tients with peritonitis diagnosed during operation without any further clinical diagnosis of sepsis and because it used a mixture of a commercially available IgG preparation with an unspecified, locally produced IgM preparation that was not generally available. A lack of availability led to the termination of the study. Three trials (43) (44) (45) were excluded because 5S immunoglobulins were used.
Twenty-seven trials were included in our systematic review (8, 10 -14, 16, 46 -65) . Their details are depicted in Table 2 .
Twenty-three trials were published as fully peer reviewed articles (10 -14, 16, 46, 48 -53, 55-62, 64, 65) , one trial in a review article (63), one trial as letter (47), and two trials as abstracts only (8, 54) . For both abstracts, a paper prepared for publication was provided by the authors so we could obtain the data necessary for the meta-analysis.
The origin of the studies revealed that the therapeutic use of immunoglobulins was investigated predominantly in Europe: 19 of the studies (70%) (8, 10, 11, 14, 46 -48, 50, 53-56, 58 -61, 63-65) were conducted in European countries (Germany 8, Turkey 6, Italy 2, Greece 1, Sweden 1, Switzerland 1); five studies (19%) (12, 49, 51, 52, 62) in Arabic or Asian countries (Saudi Arabia 1, Egypt 1, India 2, Taiwan 1); and three studies (11%) (13, 16, 57) in North or South American countries (Argentina 1, Mexico 1, United States 1).
Data were summarized separately for adults or older children and neonates.
Adults and Children. The estimate of the pooled effect of 15 trials (8, 11, 13, 14, 46 -48, 50, 53, 58 -61, 63, 64) involving 1,492 patients was RR ϭ 0.79 (95% CI 0.69 -0.90, p Յ .0003) ( Fig. 1) .
According to the a priori design, results for adult patients were aggregated for two subgroups: studies using an immunoglobulin preparation enriched with IgM and IgA molecules (IgGAM) or studies using various preparations that contained only IgG (IgG). The IgGAM preparation was evaluated in eight trials involving 560 patients (11, 13, 47, 48, 58, 59, 63, 64) . The range of the cumulative dose of IgG administered per patient was 0.18 -1.33 g/kg of body weight (BW) plus 0.03-0.21 g/kg BW IgA and 0.03-0.21 g/kg BW IgM.
In this subgroup, the estimate of the pooled effect on mortality was RR ϭ 0.66 (95% CI 0.51-0.84), which translates to a 34% relative reduction in mortality (p Յ .0009). The effects were comparable; there was no substantial heterogeneity: I 2 ϭ 0 and chi-square ϭ 6.42 (p Յ .49).
Three studies (13, 59, 64) involved exclusively postoperative surgical patients, and another three (47, 48, 58) included surgical and medical patients. One of these studies (58) was performed in patients with positive proof of endotoxinemia by a Limulus amebocyte lysate assay. From two studies in medical patients (11, 63) , one (11) was performed in neutropenic cancer patients.
IgG preparations were evaluated in seven trials involving 932 patients (8, 14, 46, 50, 53, 60, 61) . IgG was given in a cumulative dose of 0.5-2.0 g/kg BW.
The estimate of the pooled effect on mortality for this subgroup was RR ϭ 0.85 (95% CI 0.73-0.99), equivalent to a 15% relative risk reduction (p Յ .04). Three of these trials (50, 53, 61) involved exclusively surgical patients, with the trial by Grundmann and Hornung (61) being restricted to patients with positive proof of endotoxinemia by a Limulus amebocyte lysate assay. Three studies (8, 46, 60) were performed in surgical and medical patients, with the SBITS trial (8) restricted to patients with an Acute Physiology and Chronic Health Evaluation II score of 20 -35, and the trial reported by Darenberg et al. (46) restricted to patients with streptococcal toxic shock syndrome. One trial (14) was performed in pediatric intensive care patients.
The test of heterogeneity was considerably high and reached significance (chi-square ϭ 14.7, p Յ .02, I 2 ϭ 59.2%). While two studies (50, 53) reported a significant effect and four (14, 46, 60, 61) showed also a positive trend, the largest study (8) showed no effect (RR ϭ 1.05).
The comparison of IgGAM (RR ϭ 0.66) vs. IgG (RR ϭ 0.85) showed a strong trend in favor of IgGAM, yet the difference between the two estimated pooled risks failed to reach significance (z ϭ 1.70, p Յ .089).
The treatment effect did not correlate with the severity of illness (as measured by the mortality rate of the control group) or with the immunoglobulin dosage.
Neonates. In neonates, 12 trials involving 710 patients were published. The estimate of the pooled effect on mortality was RR ϭ 0.56 (95% CI 0.42-0.74, p Յ .0001) ( Fig. 2) .
Five studies (12, 51, 54, 56, 62) involving 352 patients were performed with the IgGAM preparation. The range of the cumulative dose of IgG was 0.57-0.76 g/kg BW plus 0.09 -0.12 g/kg BW IgA and 0.09 -0.12 g/kg BW IgM.
In this subgroup, the estimate of the pooled effect was RR ϭ 0.50 (95% CI 0.34 -0.73), equivalent to a 50% relative reduction in mortality (p Յ .0003). The study effects were comparable, and the test of heterogeneity was not significant: I 2 ϭ 0% and chi-square ϭ 3.01 (p Յ .56).
One study (12) reported a significant reduction of mortality, the other four a positive trend (51, 54, 56, 62) .
Polyvalent immunoglobulin preparations containing only IgG were evaluated in seven trials (10, 16, 49, 52, 55, 57, 65) involving 358 patients. The cumulative dose of IgG was 0.5-3 g/kg BW.
The estimate of the pooled effect for this subgroup was RR ϭ 0.63 (95% CI 0.42-0.96), equivalent to a 37% relative reduction in mortality (p Յ .03). The test of heterogeneity was not significant: I 2 ϭ 0% and chi-square ϭ 4.09 (p Յ .66).
One study (55) reported a significant reduction in mortality, three studies reported a positive trend (10, 16, 65) , and two studies (49, 57) showed no effect. One trial (52) showed a duplication of mortality; one neonate died in the control group and two in the treatment group.
Comparing the two treatment modalities, a small and insignificant difference in favor of IgGAM was observed (z ϭ 0.80, p Յ .42).
In neonates, we found a negative correlation (r ϭ Ϫ.76, p Յ .048) with the severity of illness (as measured by the mortality of the control groups); however, this held true only when the results reported by Chen (52) were included: In this study, an exceptionally low mortality in the control group was observed (1 of 28, respectively, 3.6%), which was doubled in the treatment group (2 of 28, respectively, 7.1%). If these results were omitted, the correlation lost significance (r ϭ Ϫ.55, p Յ .2). There was no correlation with the dosage of immunoglobulins administered.
Sensitivity Analyses. Sensitivity analyses were performed using a randomeffect model and restricting inclusion to highest quality studies.
The results were similar when a random-effect model was applied. In adults (Fig. 3) , the pooled estimate of the mortality risk was 0.70 (95% CI 0.57-0.85). The relative risk for the IgGAM preparation was almost identical (RR ϭ 0.68, 95% CI 0.53-0.86), whereas the relative risk for IgG preparations improved to 0.72 (95% CI 0.53-0.97).
Selection of eight studies of highest quality (score Ն12) in adults (8, 13, 46, 50, 53, 58, 60, 61) confirmed the results: relative risk was 0.81 (95% CI 0.69 -0.94). For IgGAM, two trials (13, 58) showed a relative risk of 0.40 (95% CI 0.21-0.76), whereas in six studies employing IgG (8, 46, 50, 53, 60, 61) the relative risk was 0.86 (95% CI 0.73-1.00).
Results for neonates ( Fig. 4) were also almost identical when using the random-effect model: The pooled estimate was RR ϭ 0.58 (95% CI 0.44 -0.77) and the relative risk for the Ig-GAM preparation was 0.53 (95% CI 0.36 -0.77) and for IgG preparations 0.65 (95% CI 0.42-0.99).
Selection of ten trials of highest quality (score Ն12) in neonates (10, 12, 16, 52, 54 -57, 62, 65) confirmed the result of the pooled effect of all trials for neonates: RR ϭ 0.51 (95% CI 0.38 -0.70). For Ig-GAM, four trials (12, 54, 56, 62) also showed an almost identical relative risk of 0.48 (95% CI 0.32-0.72), and six trials with IgG (10, 16, 52, 55, 57, 65) also confirmed the result of all trials (RR ϭ 0.56, 95% CI 0.35-0.91).
DISCUSSION
Major Findings. The aim of this study was to conduct a current and comprehensive systematic review of all published trials examining the effect of polyvalent immunoglobulins on mortality in sepsis or septic shock. We analyzed 15 trials on adults or children and 12 on-term or preterm neonates, in which the estimate of the pooled risk revealed a significant relative reduction of overall mortality of 21% and 44%, respectively.
In adults and children, we found a strong trend in favor of IgGAM. The pooled estimates of the relative risks were 0.66 vs. 0.85, equivalent to a 34% and 15% reduction of the risk to die, respectively. This might be explained by the fact that the IgGAM preparation contains higher titers of antibodies to a large variety of bacterial pathogens (66) and supplies more opsonins (2) . Also, in immune response IgM is the first line of defense, and its titers rise before those of IgG (67) . IgM requires a less extensive cascade of cooperating cells and soluble factors and leads to a more rapid and specific antibody response (68) .
In neonates, the pooled estimate of the relative risk (0.56) was even lower than in adults or children. Our meta-analysis is the first to show that the efficacy of polyvalent immunoglobulins is higher in these patients than in adults or older children. In neonates, therapy with polyclonal immunoglobulins should be un-derstood much more as a substitutional therapy than as an adjunctive therapy as for adults or older children (15) . Transplacental transfer of maternal IgG starts mostly after 34 wks of gestation, so that in premature infants there is an insufficient level of IgG. Furthermore, at an age between 4 and 24 months, the breakdown of maternal antibodies exceeds the de novo production, with the result being a transient hypogammaglobulinemia (69) .
Comparing the two treatment modalities in neonates, we found a slight difference without statistical significance: The pooled effect of five studies with the IgGAM preparation was 0.50 compared with 0.63 in patients treated with IgG, equivalent to a risk reduction of 50% vs. 37%.
Previous Systematic Reviews. The first Cochrane analysis (7) evaluated 11 of the trials that were also included in our meta-analysis. For one of the trials, we identified a second publication with a larger sample size (53) , which was included in our meta-analysis.
In addition to these 11 studies, we identified 16 further trials (8, 10 -14, 46 -48, 50, 51, 54, 55, 57, 63, 65) and also included trials using randomization by alternation (55, 65) . The lower reduction in mortality calculated for IgG in comparison with the Cochrane analysis (7) (RR ϭ 0.85 vs. RR ϭ 0.73) is certainly due to the fact that the SBITS trial (8) was also included in our analysis. This trial showed an approximately 6% higher ICU survival rate in the IgG group than in the placebo group, but this advantage could not be maintained after discharge from the ICU.
In comparison to the systematic review by Pildal and Gøtzsche (9) from the Nordic Cochrane Center, we included nine additional studies: five published after 2004 (10 -14) and four published before (16, 54, 55, 63) . Two trials were excluded because mortality was not an explicit outcome parameter (38) or because 5S immunoglobulins were used (42) .
The meta-analysis by Pildal and Gøtzsche (9) also found a comparable overall effect of a 23% relative reduction in mortality (adults and neonates). However, a subgroup analysis of four highquality studies failed to show any effect. This subgroup included studies that had adequate concealment of allocation, were double blinded and placebo controlled, and applied an intention-to-treat analysis or from which data were available allowing an intention-to-treat analysis. All trials failing to meet at least one of these criteria were considered to be of lower quality. In this subgroup of four studies, SBITS had a relative weight of Ͼ90%, so it was obvious that the overall effect would be negligible. Indeed, the highest standard in clinical trials is a double-blinded placebo con-trolled trial with concealed randomization and an intention-to-treat analysis. However, we claim that a study that is not double-blinded or does not have a concealed randomization should not necessarily been disregarded if it fulfills other criteria of methodological quality. For this reason, we decided that a meth- odological score gives a better estimate of the methodological quality. We used the score as proposed by Heyland et al (17) . Using the stricter limit of Ն12 points on this scale, we found nine studies (11, 14, 47-49, 51, 59, 63, 64 ) that failed to meet this requirement. Their exclusion did not alter the main results of our meta-analysis.
Strength and Weakness. This metaanalysis is based on methodologically heterogeneous trials: The mortality rates were not standardized as 28-day mortality was not reported in all studies. Some studies described only ICU or hospital mortality rates. Furthermore, the severity of illness and the dosage of immunoglobulins varied between the different studies. However, we did not find a significant correlation between the treatment effect and the mortality rates of the placebo group or the dosage of immunoglobulins.
A general limitation of this systematic review is that it is based on 26 smaller studies with an evidence level II and only one study with level I (8) . The eight trials performed with the IgGAM preparation in adults reflect the problem of these small studies: They are not large enough to have the power to produce significant results and are at risk of false-negative (␤-type) errors. In this group, all trials showed a positive trend, but only the trial reported by Schedel et al. (58) gained significance.
A recommendation that is drawn from level II trials is assigned grade C according to the Task Force of the American College of Critical Care Medicine and the Society of Critical Care Medicine (70) . For this reason, the positive recommendation for an adjunctive therapy with polyvalent immunoglobulins for sepsis or septic shock, which can be drawn from our data, deserves only grade C as well.
Nevertheless, Sackett (71), in his paper describing the fundamentals of evidencebased medicine, wrote, "If meta-analysis becomes generally accepted, it holds the promise of converting multiple, small Level II trials into a single, Level I overview."
We firmly believe the data demonstrated in this meta-analysis hold this promise: With five of the 27 studies reporting a significant positive effect and 19 a positive trend, the rating of the recommendation should be upgraded to grade B. This conclusion is refuted by many primarily for pecuniary reasons, and sometimes with a recommendation grade E, which denotes expert opinion (72) . We also believe that larger trialspreferentially with the IgGAM preparation-are warranted to further elucidate which patients profit from polyclonal immunoglobulins and which do not. However, the rules of evidence-based medicine should not be distorted by financial motives.
The presented data show that the Ig-GAM preparation can reduce mortality in adults by 34% and in neonates by 50%. As long as there is no better evidence, these results should be sufficient reason to use such a preparation for adjunctive therapy of severe sepsis or septic shock.
